COLORECTAL CANCER THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Colorectal Cancer Therapeutics Market Size and Trends

Colorectal cancer therapeutics market is estimated to be valued at USD 8.98 Bn in 2024 and is expected to reach USD 12.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031.

To learn more about this report, request sample copy

Global colorectal cancer therapeutics industry can witness a positive growth trend over the forecast period, owing to increasing prevalence of colorectal cancer around the world due to changing lifestyles and dietary habits of people. Moreover, rising research and development activities for development of innovative targeted therapy options for treatment of colorectal cancer can also drive the colorectal cancer therapeutics industry growth. Many companies are investing in developing drug candidates, which have fewer side effects and high selectivity for cancer cells. Furthermore, increasing awareness about early detection and treatments for colorectal cancer can boost demand for colorectal cancer therapeutics in the near future.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Insights, By Therapy Type- Clinical efficacy and versatility of chemotherapy drive its demand

In terms of therapy type, chemotherapy segment is estimated to contribute the highest market share of 45.9% in 2024, due to its effectiveness in treating colorectal cancer. This treatment utilizes various cytotoxic drugs to target cancer cells, often serving as the first-line approach. A Phase III trial revealed that combining trifluridine/tipiracil with bevacizumab significantly enhanced survival rates in patients with refractory metastatic colorectal cancer. 

Insights, By Route of Administration- Patient convenience drives the oral segment growth

In terms of route of administration, oral segment is estimated to contribute the highest share of 34.5% in 2024 in colorectal cancer therapeutics industry, due to its convenience for patients. Oral medications allow for self-administration at home, eliminating the need for infusions or injections, and this streamlines treatment and enhances accessibility. This method reduces time and travel commitments, improving adherence and clinical outcomes. 

Insights, By Distribution Channel- Integral role of hospital pharmacies in cancer care fuels growth

In terms of distribution channel, hospital pharmacies segment is estimated to contribute the highest market share of 53.1% in 2024 in colorectal cancer therapeutics industry, due to their vital role in cancer care. These pharmacies provide the necessary infrastructure and trained staff to store, prepare, and dispense complex cancer medications, ensuring a wide variety of chemotherapy agents are available. 

Regional Insights

To learn more about this report, request sample copy

Dominating Region- North America

North America is expected to dominate the colorectal cancer therapeutics market with the market share of 40.6% in 2024, driven by increased product approvals. In January 2023, the U.S. FDA granted accelerated approval to tucatinib combined with trastuzumab for treating RAS wild-type HER2-positive metastatic colorectal cancer after prior chemotherapy.

Fastest-Growing Region- Asia Pacific

Asia Pacific exhibits the fastest growth in colorectal cancer therapeutics industry with market share of 18.4% in 2024 due to improving access to healthcare, rising medical expenditures. Countries like China and India have emerged as global pharmaceutical hubs, attracting numerous pharmaceutical giants to partner manufacturing bases in the region.

Colorectal Cancer Therapeutics Market Outlook for Key Countries

U.S.’ large patient pool and high adoption of cutting-edge therapies

The U.S. colorectal cancer therapeutics sector is characterized by a substantial patient population and rapid adoption of innovative therapies. Companies like Bristol-Myers Squibb and Merck have significantly impacted the economy through the launch of novel drugs, enhancing treatment options and improving patient outcomes in this critical healthcare sector. Their ongoing research and development efforts further drive market growth.

Germany's market is supported by strong research infrastructure and universal healthcare coverage

Germany colorectal cancer therapeutics sector is bolstered by a robust research infrastructure, universal healthcare coverage, and a favorable regulatory environment for clinical trials. The presence of regional leaders like Roche and Bayer further strengthens this market, as these leverage Germany's advanced capabilities in drug development and innovation.

Rising prevalence of colorectal cancer in India

India's colorectal cancer therapeutics market is significantly influenced by rising incidence rates, which is largely attributed to lifestyle changes, such as the adoption of calorie-rich diets and reduced physical activity, alongside an aging population. These factors contribute to a growing patient pool, necessitating enhanced therapeutic options and early intervention strategies.

China’s Improved healthcare infrastructure

China's colorectal cancer therapeutics industry is rapidly expanding, driven by improvements in healthcare infrastructure and increased access to both branded and generic drugs. As patients gain better access to treatments in public and private settings, the demand for effective therapies rises, enhancing overall market growth. This progress reflects the government's commitment to universal health coverage and improved healthcare services.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Top Strategies Followed by Colorectal Cancer Therapeutics Market Players

• Established players in the colorectal cancer therapeutics industry focuses heavily on research and development to deliver innovative treatment solutions. Companies like Roche, Amgen, and Bristol-Myers Squibb invest over 15% of annual revenue into R&D. These conduct clinical trials to refine drug candidates and biomarkers that enhance precision oncology.
• Mid-sized companies concentrate on providing affordable treatment alternatives. For example, Varian Medical Systems works with local providers to offer flat panel digital radiotherapy devices at reduced rates. Their streamlined manufacturing helps pass cost savings to consumers in emerging markets.
• Small biotechs focuses on niche cancer subtypes or novel delivery systems. StemoniX develops human bioengineered neural platforms for personalized therapy screening and toxicity testing. Its specialized approach addresses the needs of rare patient segments left behind by blockbuster drugs. Another strategy is leveraging digital platforms. Biofourmis uses artificial intelligence to power virtual care and improve treatment adherence for colorectal cancer patients.

Emerging Startups in the Colorectal Cancer Therapeutics Market

• Several startups are using innovative technologies like machine learning and liquid biopsies. Anthropic develops constitutional AI to stratify patient risks and select optimal treatments based on molecular profiles. Its technology could transform clinical decision-making processes.
• Sustainability is increasingly prioritized by emerging companies. NuMat Technologies manufactures biodegradable polymers as safer, eco-friendly alternatives to traditional medical plastics. Its materials could reduce environmental contamination from medical waste.
• Niche startups also address unmet needs for advanced treatment. GastroIntestinal Oncology focuses on biomarker research and immunotherapies specific to gastrointestinal cancers. Its specialized approach targets the unique biology of these tumors. Anthropic collaborates with hospitals to refine AI models, while Grail works with diagnostic companies to expand patient access.

Colorectal Cancer Therapeutics Industry News

• In May 2023, Biocartis Group NV, a molecular diagnostics company, and HiloProbe, a biotechnology company that focuses on personalizing colorectal cancer diagnostics, announced a collaboration that will initially focus on the commercialization of ColoNode, a CE-marked IVD gene expression signature test that can help detect nodal metastasis in patients with colorectal cancer
• In March 2023, Alembic Pharmaceuticals, an India-based pharmaceutical company, received final approval from the U.S. FDA for Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) pharmacy bulk vial. The injection is used for the treatment of patients with adenocarcinoma of colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma, and pancreatic adenocarcinoma

In February 2023, MEI Pharma, Inc., a clinical-stage pharmaceutical company, and Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company, announced a definitive merger agreement for an all-stock transaction forming a company combining MEI and Infinity's expertise and resources to advance a robust pipeline of three clinical-stage oncology drug candidates. ME-344, a novel tumor selective mitochondrial inhibitor targeting the OXPHOS pathway, is one of the drug candidates being tested in patients with relapsed colorectal cancer in combination with bevacizumab (AVASTIN).

Key Takeaways from Analyst

Colorectal cancer therapeutics market growth is driven by increasing prevalence of colorectal cancer worldwide. North America currently dominates due to high awareness and technological advancements aiding early detection. However, Asia Pacific is expected to witness faster adoption due to growing healthcare expenditure and expanding diagnostic facilities.

While targeted therapies are gaining traction, immunotherapy drugs will witness higher uptake. Various immuno-oncology agents in the pipeline can hamper the market growth if clinical trials showcase efficacy over existing therapies.

Market Report Scope

Market Dynamics

Market Driver - Increasing Awareness of Colorectal Cancer (CRC)

Increasing awareness programs regarding colorectal cancer can increase the diagnosis and treatment rate. For instance, in April, 2023, Beijing Genomics Institute Group released its State of Colorectal Cancer Awareness Report, marking the first-ever global survey report on the world's third most common cancer. This report seeks to better understand the global state of CRC awareness, as well as attitudes and actions towards CRC screening for average risk groups and CRC screening for hereditary genetic risk groups.

Market Challenge - Side effects of therapeutics

Colorectal cancer therapeutics market faces challenges like side effects associated with various treatment options. Common chemotherapeutic drugs can cause severe side effects like nausea, fatigue, hair loss, and peripheral neuropathy, significantly affecting patients' quality of life and sometimes leading to treatment discontinuation. Targeted therapies and immunotherapies can induce immune-related adverse events. Effective management of these side effects is crucial for improving adherence to therapy and clinical outcomes, necessitating focus on developing novel therapeutics with better safety profiles.

Market Opportunity - Advancement in the Colorectal Cancer (CRC) Treatment

Advancement in the colorectal cancer treatment offers significant opportunities. For instance, as per the New England Journal of Medicine in October 2022, a group of researchers enrolled 84,585 men and women aged 55 to 64 years old for colorectal cancer clinical trials who had not undergone prior colorectal cancer screening. The researchers noted that 15 participants experienced major bleeding after polyp removal. However, no perforations or screening-related deaths occurred within 30 days of colonoscopy.

Market Segmentation

•  Therapy Type Insights (Revenue, USD, 2019 – 2031)
• • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Immunotherapy
    • Immune Checkpoint Inhibitors
    • Oncolytic Virus Therapy
    • Others
  • Targeted Therapy
    • Monoclonal antibodies
    • Small molecule inhibitors
  • Others
•  Route of Administration Insights (Revenue, USD, 2019 – 2031)
• • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others
•  Distribution Channel Insights
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD, 2019 – 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Sanofi
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Ono Pharmaceutical Co. Ltd
  • ALX Oncology Inc.
  • Daiichi Sankyo Company, Limited
  • Pfizer Inc.
  • Exelixis, Inc.
  • SOTIO Biotech AG
  • AB Science
  • BioNTech SE
  • Effector Therapeutics, Inc.
  • Treos Bio Limited